Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

MeiraGTx

- PMLiVE

J&J and LDC to join forces on unmet medical needs

Collaboration will aim to find and accelerate new potential treatments

- PMLiVE

J&J signs $1bn deal with Achillion for hepatitis C therapies

Will license three candidates from Achillion Pharma

- PMLiVE

FDA approves J&J’s schizophrenia drug Invega Trinza

New version of Invega is the first treatment for the condition to require only four doses a year

- PMLiVE

J&J takes external advice on compassionate use

Drugmaker will run a pilot for a review of one late-stage project

IBM sets up Watson Health unit to advance its data ambitions

Will also partner with Apple, J&J and Medtronic and acquire two big data companies

- PMLiVE

Google and J&J team up for robotic surgery

Two firms looking to revolutionise medical technology

- PMLiVE

Imbruvica shines in combination trial

Showed significant increase in progression-free survival

- PMLiVE

J&J sells Cordis unit to Cardinal Health for $1.94bn

Marks J&J’s exit from the cardiovascular stent market

- PMLiVE

Complaints about UK medical advertising drop

And this year the MHRA will be vetting adverts to promote a ‘right first time’ approach

- PMLiVE

J&J gets quicker review for schizophrenia depot in US

Could be ready to market by the middle of this year

- PMLiVE

Biosimilar Remicade reaches market in Japan and India

Nippon Kayaku’s version of arthritis drug was approved in July

- PMLiVE

Olysio drives J&J pharma sales

But hepatitis C drug set to face serious competition from Gilead Sciences

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links